|
ALL |
MONO-DUAL THERAPY |
HAART |
p |
Term (weeks) |
38.1±2 |
38.5±2.4 |
37.8±1.7 |
<0.0001 |
Number of preterm infants (%) |
42/292 (14.4%) |
19/129 (14.7%) |
23/163 (14.1%) |
NS |
Birth weight (g) |
2925±569 |
2982±622 |
2872±525 |
<0.04 |
AZT dose per Kg per days (mg) |
7.7±0.7 |
7.8±0.7 |
7.7±0.7 |
NS |
Length of post natal exposure (days) |
35.7±8.3 |
38.6±7.8 |
33.3±7.8 |
<0.0001 |
AZT (%) |
217/307 (71%) |
86/136 (63%) |
131/171 (77%) |
NS |
AZT+3TC*, ** (%) |
54/307 (18%) |
37/136 (27%) |
17/171 (10%) |
0.001 |
AZT + NVP*** (%) |
36/307 (12%) |
13/136 (10%) |
23/171 (13%) |
NS |
*: 28 patients included in the ANRS075 study (see text);
**: 1 child received AZT+3TC+LPV;
***: 10 mother-child pairs included in the pACTG316-ANRS083 study (nevirapine
arm; see text) |
